Shaoxing Central Hospital
9
5
6
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 9 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
Observational Study of ASCVD Risks of Type 2 Diabetes in East China
Role: collaborator
A Multicenter, RAndomlzed, coNtrolled, umBrella Trial fOr Minimally Invasive Neurosurgery With Al-assisted Robotic guidanCe for Hemorrhagic Stroke: Large Basal Ganglia Hemorrhage
Role: collaborator
Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma
Role: collaborator
A Study on the Impact of Online Positive Psychological Intervention on the Mental Health and Quality of Life of Crohn's Disease Patients
Role: collaborator
Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma
Role: collaborator
Metformin Hydrochloride and Empagliflozin Tablets in the Treatment of Type 2 Diabetes
Role: collaborator
A Study of the Efficacy of Troxerutin in Preventing Thrombotic Events in COVID-19 Patients
Role: collaborator
Improving In-hospital Stroke Service Utilisation in China
Role: collaborator
Investigation on the Practice Status of Emergency Stuff
Role: collaborator
All 9 trials loaded